| Pharmaceutical active ingredients: |
| Doxorubicin Hydrochloride |
| Available forms, composition and doses of Adriblastine: |
| Injectable; Injection; Doxorubicin Hydrochloride 2 mg / ml |
| Adriblastine medical category: |
| Human:Antineoplastic agentsCytotoxic chemotherapy |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| L01DB01 - Doxorubicin |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| Pfizer |
| Related documents and information about Adriblastine: |
| Adriblastina PFS prescribing information (PDF) |
| Trade name |
Active ingredients |
Pharmaceutical company |
|
Adriblastina | Doxorubicin Hydrochloride | Pfizer; Deva Holding Ilac Grubu |
| Adriblastina PFS | Doxorubicin Hydrochloride | Pfizer |
| Adriblastina Rapid Dissolution | Doxorubicin Hydrochloride | Pfizer; Zuellig Pharma |
| Adriblastina RD | Doxorubicin Hydrochloride | Pfizer; Zuellig Pharma |
| Adriblastina RTU | Doxorubicin Hydrochloride | Pfizer |
| Adricin | Doxorubicin Hydrochloride | Novell Pharmaceutical Laboratories |
| Adrim | Doxorubicin Hydrochloride | Fresenius; Biogalenic Laboratorios; Bioscience; Dabur Pharmaceuticals; Medica Care; Metro Drug Distribution |
| Adrimedac | Doxorubicin Hydrochloride | Medac; Pharmachemie |
| Adrosal | Doxorubicin Hydrochloride | Naprod Life Sciences; Ambica International Trading Corporation; Sherryville Medical & Healthcare Products; VHB Pharmaceuticals |
| Axibin | Doxorubicin Hydrochloride | Korea United Pharmaceutical; Qualimed Pharma |